Date: January 27, 2020
To: Calgary and South Zone: Physicians, Nurses and Laboratory Staff
From: Dr. Hossein Sadrzadeh, Section Chief, Clinical Biochemistry, South Sector
Re: Discontinuation of Reverse T3 Test

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message:
• Effective January 31, 2020, Reverse T3 testing will be discontinued in the Calgary and South zones.

Why this is Important:
• Current practice guidelines do not advise or require the measurement of rT3 in the management of thyroid diseases.
• The Clinical Practice Guideline for Thyroid Dysfunction from the Towards Optimized Practice program of the Alberta Medical Association recommends appropriate use of TSH, FT4 and FT3 (http://topalbertadoctors.org/cpgs.php).
• A patient with normal TSH, FT4 and FT3 observed after 3 months of amiodarone treatment should be followed with TSH measurement every 6 – 12 months.
• An elevated TSH suggests the development of amiodarone induced hypothyroidism.
• Comparison of FT4 and FT3 to previous values and clinical assessment are required to determine the status of these patients.

Inquiries and feedback may be directed to:
Hossein Sadrzadeh, PhD, Section Chief, Clinical Biochemistry, South Sector, 403-770-3759, Hossein.Sadrzadeh@albertaprecisionlabs.ca

This bulletin has been reviewed and approved by:
Hossein Sadrzadeh, PhD, DABCC, FAACC, Chief of Clinical Biochemistry Section, South Sector, APL
Leland Baskin, MD, FCAP, FAACC, Associate Medical Director, South Sector

www.albertaprecisionlabs.ca